By 2024, the storeable value DBS industry will account for approximately 8% of the Asia-Pacific market.
GlobalData said the Indian deep brain stimulator (DBS) market is expected to grow at a CAGR of over 10% by 2033 due to the huge gap in movement disorder treatment.
The country’s charging DBS industry is expected to account for approximately 8% of the Asia-Pacific market by 2024.
This growth is attributed to increasing patient base, cost advantages, availability of skilled neurosurgeons, and expanding medical infrastructure.
“As life expectancy increases globally, age-related neurodegenerative diseases are becoming increasingly common,” said Divya Soni, medical device analyst at GlobalData.
However, DBS systems have significant limitations, such as a limited battery life of only three to five years. This requires regular surgical replacement with non-rechargeable models, thereby increasing patient burden and surgical risk.
“The introduction of advanced DBS technology provides a transformative solution that delivers personalized, data-driven treatments, sets new standards in precision care and improves quality of life across the country,” Soni added.
